CIK 0001621227 · Non-accelerated filer<br>Smaller reporting company
Adaptimmune Therapeutics PLC
Sign in to watch- Ticker
- ADAPY
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 44 1235 430000
- Business address
- 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom
- Former names
- Adaptimmune Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 10 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-05-16 | Noble James Chief Executive Officer | Option exercise | +1,773,100 | $0.14 | $254K | 1,773,100 |
| 2019-01-14 | Binder-Scholl Gwendolyn Knowlton Chief Technology Officer | Sale | −1,514 | $5.37 | $8K | 2,487 |
| 2019-01-14 | Bertrand William C JR Chief Operating Officer | Sale | −2,271 | $5.37 | $12K | 3,731 |
| 2019-01-14 | Amado Rafael President, R & D | Sale | −3,028 | $5.37 | $16K | 4,974 |
| 2019-01-14 | Rawcliffe Adrian Chief Financial Officer | Sale | −3,084 | $5.37 | $17K | 3,318 |
| 2019-01-04 | Bertrand William C JR Chief Operating Officer | Grant or award · Option to purchase Ordinary Shares | +1,006,224 | 1,006,224 | ||
| 2019-01-04 | Bertrand William C JR Chief Operating Officer | Grant or award · Option to purchase Ordinary Shares | +224,724 | 224,724 | ||
| 2019-01-04 | TAYTON-MARTIN HELEN KATRINA Chief Business Officer | Grant or award · Option to purchase Ordinary Shares | +1,006,224 | 1,006,224 | ||
| 2019-01-04 | TAYTON-MARTIN HELEN KATRINA Chief Business Officer | Grant or award · Option to purchase Ordinary Shares | +224,724 | 224,724 | ||
| 2019-01-04 | Rawcliffe Adrian Chief Financial Officer | Grant or award · Option to purchase Ordinary Shares | +1,257,744 | 1,257,744 | ||
| 2019-01-04 | Rawcliffe Adrian Chief Financial Officer | Grant or award · Option to purchase Ordinary Shares | +280,896 | 280,896 | ||
| 2019-01-04 | Amado Rafael President, R & D | Grant or award · Option to purchase Ordinary Shares | +1,006,224 | 1,006,224 | ||
| 2019-01-04 | Amado Rafael President, R & D | Grant or award · Option to purchase Ordinary Shares | +224,724 | 224,724 | ||
| 2019-01-04 | Noble James Chief Executive Officer | Grant or award · Option to purchase Ordinary Shares | +2,515,536 | 2,515,536 | ||
| 2019-01-04 | Noble James Chief Executive Officer | Grant or award · Option to purchase Ordinary Shares | +561,792 | 561,792 | ||
| 2018-12-17 | Alleva Lawrence M Director | Purchase | +47,280 | $0.84 | $40K | 47,280 |
| 2018-10-01 | Binder-Scholl Gwendolyn Knowlton Chief Technology Officer | Sale | −25,000 | $13.79 | $345K | 0 |
| 2018-09-07 | Viswanathan Ravi 10% owner | Purchase | +3,000,000 | $1.67 | $5.0M | 82,978,668 |
| 2018-09-07 | Viswanathan Ravi 10% owner | Purchase | +12,000,000 | $1.67 | $20.0M | 12,000,000 |
| 2018-09-07 | Sonsini Peter W. 10% owner | Purchase | +3,000,000 | $1.67 | $5.0M | 82,978,668 |
Page 16 of 23 · 454 trades